IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.
Analytics Powerhouse | IQVIA leads in healthcare analytics and clinical research, with $15.7B revenue and $2.9B EBITDA. Explore its diverse portfolio across technology, R&D, and medical solutions. |
Mixed Performance | Delve into IQVIA's financial results, revealing strong Technology & Analytics growth amid challenges in R&D Solutions. Learn about narrowed guidance and future projections. |
Industry Headwinds | Uncover the impact of healthcare policy changes and market dynamics on IQVIA's operations, including the effects of the Inflation Reduction Act on research activities. |
Future Growth Drivers | Analysts project growth re-acceleration, with price targets ranging from $165 to $270. Discover how AI collaboration and diversification strategy position IQVIA for success. |
Metrics to compare | IQV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIQVPeersSector | |
---|---|---|---|---|
P/E Ratio | 26.3x | 17.5x | −0.6x | |
PEG Ratio | −2.58 | 0.03 | 0.00 | |
Price/Book | 5.6x | 1.3x | 2.6x | |
Price / LTM Sales | 2.1x | 1.7x | 3.3x | |
Upside (Analyst Target) | 15.1% | 80.9% | 37.4% | |
Fair Value Upside | Unlock | 16.6% | 4.5% | Unlock |